Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07400965
PHASE2

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Sponsor: Glaukos Corporation

View on ClinicalTrials.gov

Summary

This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.

Official title: Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

250

Start Date

2025-12-05

Completion Date

2026-11

Last Updated

2026-02-27

Healthy Volunteers

No

Interventions

DRUG

GLK-321 low dose BID

Twice daily administration of low dose GLK-321 to both eyes

DRUG

GLK-321 mid dose BID

Twice daily administration of mid dose GLK-321 to both eyes

DRUG

GLK-321 high dose BID

Twice daily administration of high dose GLK-321 to both eyes

DRUG

GLK-321 high dose QD

Once daily administration of high dose GLK-321 to both eyes

DRUG

Placebo BID

Twice daily administration of placebo to both eyes

Locations (1)

Glaukos Clinical Study Site

Newport Beach, California, United States